Resmed Corp. has agreed to acquire Noctrix Health Inc. for $340 million, boosting its sleep health portfolio. Noctrix has developed Nidra, a wearable neuromodulation device which treats restless legs syndrome (RLS) without disrupting sleep. With RLS impacting approximately 7% of adults globally, including about 17 million people in the U.S., the technology offers a non-drug option that could potentially treat a significant proportion of this patient population.

In good news for those who toss and turn in the night with restless legs syndrome and their bed partners, bioelectronic technology appears to reduce the disruptive and uncontrolled movement. Researchers claimed that the NTX100 tonic motor activation (TOMAC) therapy, developed by Noctrix Health Inc., has the potential to transform treatment for people with restless legs syndrome (RLS) who are resistant to medications.